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We  conducted a comprehensive and systematic search of the literature on the use of platelet-
rich plasma (PRP) in the treatment of osteoarthritis, using the Medline, Lilacs, Cochrane and
SciELO databases, from May 2012 to October 2013.
A total of 23 studies were selected, with nine being controlled trials and, of these, seven
randomized, which included 725 patients. In this series, the group receiving PRP showed
improvement in pain and joint function compared to placebo and hyaluronic acid. The
response lasted up to two years and was better in milder cases.
However it was found that there is no standardization in the PRP production method,
neither in the number, timing, and volume of applications. Furthermore, the populations
studied were not clearly described in many studies. Thus, these results should be analyzed
with  caution, and further studies with more standardized methods would be necessary for
a  more consistent conclusion about the PRP role in osteoarthritis.
© 2015 Elsevier Editora Ltda. All rights reserved.
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r  e  s  u  m  o
Fez-se uma pesquisa abrangente e sistemática da literatura sobre o uso de plasma rico
em  plaquetas (PRP) no tratamento da osteoartrite nas bases de dados do Medline, Lilacs,
Cochrane e SciELO, de maio de 2012 a outubro de 2013.
Foram selecionados 23 estudos, entre eles nove ensaios controlados e, desses, sete ran-domizados, os quais incluíram 725 pacientes. Nessa casuística, o grupo que recebeu PRP
apresentou melhoria na dor e na func¸ão articular quando comparado ao que recebeu placebo
e  ácido hialurônico. A resposta durou até dois anos e foi melhor nos casos mais leves.
Entretanto, veriﬁcou-se que não há uma padronizac¸ão no método de obtenc¸ão do PRP, bem
como no número, intervalo e volume de aplicac¸ões. Além disso, as populac¸ões estudadas∗ Corresponding author.
E-mail: eduardo knop@hotmail.com (E. Knop).
http://dx.doi.org/10.1016/j.rbre.2015.07.002
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também não foram claramente descritas em muitos estudos. Desse modo, esses resultados
devem ser analisados com cautela e seriam necessários novos estudos com métodos mais
padronizados para uma conclusão mais consistente sobre o papel do PRP na osteoartrite.
©  2015 Elsevier Editora Ltda. Todos os direitos reservados.
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introduction
lthough osteoarthritis (OA) is one of the most prevalent
usculoskeletal diseases in the world, its treatment is still
elatively limited.1 The Osteoarthritis Research Society Inter-
ational notes that there is little evidence that the currently
sed drugs have effective action against the progression of the
isease.2
A relatively new strategy for the treatment of OA is the use
f cell elements and biomediators of tissue response. In this
ontext, the platelet-rich plasma (PRP) has been conﬁgured as
 perspective for improving clinical and structural outcomes
y delivering a high concentration of growth factors that medi-
te cartilage healing and remodeling. Its potential has been
hown in vitro and in vivo studies, however its real efﬁcacy in
A is not well established.3
Thus, this study has the purpose to present some technical
spects for obtaining PRP, possible mechanisms of action and
 review of its use in knee osteoarthritis.
ethods
e  conducted a comprehensive and systematic litera-
ure search using MEDLINE, LILACS, Cochrane and SciELO
atabases, from May 2012 to October 2013. The key words used
ere “platelet-rich plasma,” “platelet-rich growth factor”,
osteoarthritis”, “hip”, “knee”, “ankle”, “human” and “carti-
age”. The studies found in the initial search were reviewed
nd additional references were also evaluated and included
here relevant. The search was limited to studies performed
n humans. The selected articles were read in full by two
eviewers for analysis of their methods and their limitations.
isagreements were discussed for a consensus, with the medi-
tion of a third author.
The quality of the studies analyzed was initially classiﬁed
ccording to randomization. Then we proceeded to the eval-
ation of the following items: type of control group (active
ontroller – hyaluronic acid – or placebo), double-blind evalua-
ion (with description of SHAM procedure), number of treated
atients, deﬁnition of radiographic and level of pain in the
nclusion criteria, deﬁnition of exclusion criteria, description
f blinding and randomization process, intention to treat anal-
sis, assessment tools (whether including OMERACT criteria
r not), description of the process to obtain PRP, platelet con-
entration, volume injected, guided-injection performance,
umber of injections in the treated and control groups, and
eport of adverse events.
A total of 23 studies (Fig. 1 and Tables 1 and 2) were selected,
ith nine being controlled trials, and of these, seven random-
zed, which included 725 patients. In this review some resultsof other 13 non-controlled studies, and also a retrospective
cohort were also listed.
Mechanism  of  action  of  PRP
When PRP is injected into the injured site, platelets are
activated by endogenous thrombin and/or intra-articular
collagen.4 Once activated, there is secretion of growth factors
by degranulation of the -granules.5 Among secreted sub-
stances we can ﬁnd: platelet-derived growth factor (PDGF),
interleukin-1 receptor antagonist (IL-1RA), soluble receptor of
tumor necrosis factor  (TNF-RI), transforming growth factor 
(TGF-), platelet factor 4 (PF4), vascular endothelial growth fac-
tor (VEGF), epidermal growth factor (EGF), insulin-like growth
factor (IGF), osteocalcin (Oc), osteonectin (On), ﬁbrinogen, vit-
ronectin, ﬁbronectin and thrombospondin-1 (TSP-1).6
Many of these mediators act as anti-catabolic and anti-
inﬂammatory agents. The antagonist of IL-1 receptor inhibits
activation of NFB gene, cytokine involved in apoptosis and
inﬂammation process.4,7 Moreover, the soluble receptors of
the tumor necrosis factor bind to TNF-, preventing its
interaction with cellular receptors and its pro-inﬂammatory
signaling. TGF-1 also acts as a factor inhibiting cartilage
degradation, regulating and enhancing gene expression of tis-
sue inhibitors of metalloproteinases (TIMP-1).8 Other factors
such as IGF-1, PDGF and TGF-1 favor the stabilization of car-
tilage by controlling the metabolic functions of chondrocytes
and subchondral bone, maintaining the homeostasis between
the synthesis and degradation of proteoglycans, and stimulat-
ing the proliferation of chondrocytes.9,10 It was also found that
platelet growth factors stimulate synovial ﬁbroblasts to syn-
thesize hyaluronic acid.9 These mechanisms are illustrated in
Fig. 2.
Technical  aspects  for  obtainment  of
platelet-rich  plasma
PRP is obtained by centrifuging the autologous venous blood,
causing a high concentration of platelets in a small vol-
ume  of plasma.11 There is no standardization regarding the
speed, duration and number of centrifugations needed, nei-
ther which layer exactly is removed from the precipitate after
this process.3
After the separation of the blood component rich in
platelets, platelet activation can be stimulated artiﬁcially. The
most commonly used activator is calcium chloride, which
stimulates the production of thrombin, leading to release of
growth factors. Other activators described are bovine throm-
bin and type I collagen. It is believed that the latter leads to a
more  gradual and durable release of the platelet granules, in
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Fig. 1 – PRP action mechanisms. TNF, tumor necrosis factor ; TNFR, tumor necrosis factor  receptor; IL-1 interleukin-1; IL-1R, interleukin-1 receptor; TGF , transforming
growth factor ; TIMP, tissue inhibitor of metalloproteinases; PDGF, platelet-derived growth factor; IGF, insulin-like growth factor; FGF-2, ﬁbroblast growth factor-2.
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Table 1 – Platelet-rich plasma for the treatment of knee osteoarthritis – prospective, randomized and controlled trials.
Study Mean
age
(years)
Aspects related to PRP Study design Assessments Results
Centrifugation Injections
interval
Volume
(ml)
Platelet
count
Radiographica
grade
Randomization/
Method
Double-blind/
SHAM
procedure
Intention
to treat
Treated
(N)
Controls
(N)
Analyzed
parameters
Sánchez
201225
60.5 ± 7.9
(PRP)
58.9 ± 8.2
(HA)
Single
580 g
(8 min)
3 injections
Weekly (PRP
and HA)
2 NS 1–3 (Ahlbäck) Yes
Patients were
identiﬁed by
numbers
Yes
Yes
Yes 89 87 HA WOMAC
Lequesne
0  and 24
weeks
PRP reduced
WOMAC by
50%.
Secondary
outcomes with
no difference.
Vaquerizo
201326
62.4 ± 6.6
(PRP)
64.8 ± 7.7
(HA)
Single
580 g
(8 min)
3 Injections
Weekly (PRP)
Single (AH)
2 NS 2–4 (K-L) Yes
Through
software
No
No
Yes 48 48 HA WOMAC
Lequesne
OMERACT-
OARSI
0, 24 and 48
weeks
PRP better
than HA at 24
and 48 weeks.
Li  201128 57.6 (PRP)
58.2 (H)A
Double
2000 rpm
(10 min each)
3  Injections
Every 3 weeks
(PRP and HA)
3.5 (819.4 ± 136,3)
×  106 ml–1
1–4 (K-L) Yes
NS
NS
No
Yes 15 15 HA IKDC
WOMAC
Lequesne
3, 4  and 6
months
PRP e HA
showed
beneﬁt.
PRP  showed to
be better in
the ﬁnal
evaluation at 6
months.
Spaková
201229
52.8 ± 12.4
(PRP)
53.2 ± 14.5
(HA)
Triple
3200 rpm
(15 min)
1500 rpm
(10 min)
3200 rpm
(10 min)
3 Injections
Weekly
(PRP e HA)
3 680 ± 132
× 106 ml–1
1–3 (K-L) Yes
NS
NS
Yes
NS 60 60 HA WOMAC
NRS
3  and 6
months
PRP better
than HA.
Side effects
(level of pain)
more evident
in the PRP
group, which
remitted in
2 days.
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Table 1 – (Continued)
Study Mean
age
(years)
Aspects related to PRP Study design Assessments Results
Centrifugation Injections
interval
Volume
(ml)
Platelet
count
Radiographica
grade
Randomization/
Method
Double-blind/
SHAM
procedure
Intention
to treat
Treated
(N)
Controls
(N)
Analyzed
parameters
Cerza
201230
66.5 ± 1.3
(PRP)
66.2 ± 10.6
(HA)
Double
NS
4 Injections
Weekly
(PRP e HA)
5.5 NS 1–3 (K-L) Yes
NS
No
No
Yes 60 60 HA WOMAC 4, 12 and 24
weeks
PRP better
than HA,
regardless of
grade of
osteoarthritis.
Filardo,
201231
55 (PRP)
58 (HA)
Double
1480 rpm
(6 min)
3400 rpm
(15 min)
3 Injections
Weekly
(PRP e HA)
5  NS 1–3 (K-L) Yes
NS
Yes
Yes
Yes 55 54 HA IKDC
EQ-VAS
Tegner
KOOS
2, 6 and 12
months
No difference
between PRP
and HA.
Tendency of
superiority of
PRP in lower
grades of
osteoarthritis
Patel
201333
53.1 ± 11.6
(Group A)
51.6 ± 9.2
(Group B)
53.7 ± 8.2
(Group C)
Single
1500 rpm
(15 min)
Group A:
Single (PRP)
Group B: 2
ijections, one
every 3 weeks
(PRP)
Group C:
Single
(placebo)
8 31,014
× 106 L–1
1–2(Ahlbäck) Yes
Through
software
Yes
Yes
No 26
(Group A)
25
(Group B)
23 saline WOMAC 6; 12 and 24
weeks
PRP superior to
placebo
No difference
between one
or two
Injections
N, number of individuals; PRP, platelet-rich plasma; HA, hyaluronic acid; OA, osteoarthritis; BMI, body mass index; K-L, Kellgren-Lawrence; NE, not speciﬁed; WOMAC, Western Ontario and McMaster
Universities index; OMERACT-OARSI, Outcome Measures for Rheumatology Committee and Osteoarthritis Research Society International Standing Committee for Clinical Trials Response Criteria
Initiative; NRS, Numeric Rating Scale; KOOS scale, Knee injury and Osteoarthritis Outcome Score; EQ-VAS, EuroQol visual analog scale; IKDC, International Knee Documentation Committee; min,
minutes; rpm, rotations per minute; g, unit of centrifugal force.
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Table 2 – Platelet rich plasma for the treatment of human osteoarthritis – nonrandomized, non-controlled, cohort trials.
Studies Type of study Joint Centrifugation Treated
(N)
Controls
(N)
Injections (N)
interval
Analyzed
parameter
Assessment Results
Say27 Prospective
Controlled
Non-randomized
Knee  Single 45 45 HA Injection Single KOOS
VAS
0,  3 and 6 months PRP superior to HA.
Better cost-beneﬁt of
PRP
Kon32 Prospective
Controlled
Non-randomized
Knee  Double 50 50 HAAP
50 LWHA
3 injections
Biweekly
IKDC
EQ-VAS
2  and 6 months PRP showed beneﬁt;
Better results in young
people and lower degree
of degeneration
Sánchez34 Retrospective Knee Single 30 30 HA 3 injections
Weekly
WOMAC 8  weeks PRP superior to HA
Kon35 Prospective Knee Double 100 None 3 injections
Every 3 weeks
IKDC
EQ-VAS
2,  6 and 12 months PRP showed beneﬁt;
Better results in young
people and lower degree
of degeneration
Filardo36 Prospective Knee Double 91 None 3 injections
Every 3 weeks
IKDC
EQ-VAS
2,  6, 12 and 24
months
PRP showed beneﬁt;
Decrease in response
after 12 months, but
higher than the initial
scores
Sampson37 Prospective Knee Single 14 None 3 injections
Monthly
Brittberg- Peterson
VAS
KOOS
Thickness
2,  5, 11, 18 and 52
weeks
PRP showed beneﬁt;
No increase in thickness
of cartilage
Ana Wang-
Saegusa38
Prospective Knee Single 261 None 3 injections
Biweekly
VAS
SF-36
WOMAC
Lequesne
6  months PRP showed beneﬁt
Napolitano39 Prospective Knee Single 27 None 3 injections
Weekly
WOMAC
NRS
7  days and 6
months
PRP showed beneﬁt
Sanchez40 Prospective Hip Single 40 None 3 injections
Weekly
WOMAC
VAS
HHS
6–7  weeks and 6
months
PRP showed beneﬁt
Jang41 Prospective Knee Double 65 None Injections single WOMAC 1, 3,6 9 and 12
months
PRP showed beneﬁt
Battaglia42 Prospective
Pilot study
Hip  Not speciﬁed 20 None 3 injections
Biweekly
HHS
WOMAC
3,  6 and 12 months PRP showed beneﬁt;
Decrease in response
after 3 months, but
higher than the initial
scores.
Better results in young
people.
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Table 2 – (Continued)
Studies Type of study Joint Centrifugation Treated
(N)
Controls
(N)
Injections  (N)
interval
Analyzed
parameter
Assessment Results
Halpern43 Prospective
Pilot Study
Knee Not speciﬁed 17 None Injections Single VAS
WOMAC
MRI de knee
1,  3, 6 and 12
months
PRP showed beneﬁt
There was no reduction
in cartilage thickness in
MRI
Gobbi44 Prospective Knee Single 50 None 2 injections
Monthly
KOOS,
VAS
Tegner
IKDC
Marx  scores
0,  6 and 12 months PRP showed beneﬁt;
There was no difference
between patients that
were previously
approached and
patients with no
previous intervention.
Hart45 Prospective Knee Double 55 None 6 injections
Weekly. After
maintenance
with 3 quarterly
injections
Lysholm
Tegner
IKDC
Cincinnati
Knee MRI
0  and 12 months PRP showed beneﬁt
There was no reduction
in cartilage thickness in
MRI
Filardo46 Prospective Knee Double 72 PRGF
72 PRP
None 3 injections
Each 3 weeks
IKDC
EQ-VAS
Tegner scores
2,  6 and 12 months Similar beneﬁt between
methods;
Double centrifugation
shows more side effects
Dhollander47 Prospective Knee Double 5 None Injections Single VAS
KOOS
Tegner Score
MOCART
0,  12 and 24
months
Procedure leads to
clinical improvement;
No response in the
analysis of cartilage in
MRI
N, number of individuals; WOMAC, Western Ontario and McMaster Universities index; NRS, Numeric Rating Scale; KOOS scale, Knee injury and Osteoarthritis Outcome Score; EQ-VAS, EuroQol visual
analog scale; VAS, visual-analog scale; IKDC, International Knee Documentation Committee; SF-36, Short Form (36) Health Survey; HHS, Harris Hip Score; AOFAS, American Orthopaedic Foot and Ankle
Society; AHFS, Ankle-Hindfoot Scale; MOCART, Magnetic Resonance Observation of Cartilage Repair Tissue; PRP, platelet-rich plasma; HA, hyaluronic acid; LWHA, low molecular weight hyaluronic
acid; HWHA, High molecular weight hyaluronic acid; SF, saline; MRI, resonance magnetic imaging.
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Total number of studies
(23)
n=1914
Controlled
(9)
n=965
Non Controlled
(14)
n=949
Non Randomized
(2)
n=240
Randomized
(7)
n=725
PRP vs. Placebo
(1)
n= 74
PRP vs. HA
(2)
n=240
PRP vs. HA
(6)
n=651
Fig. 2 – Platelet-rich plasma (PRP) in the treatment of human osteoarthritis. PRP, platelet-rich plasma; HA, hyaluronic acid; n,
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ontrast to the path of thrombin, which induces an immediate
elease of growth factors.12 Regardless of the activator used, it
s recommended that the component is applied immediately
fter platelet activation.13
Recently some authors14 developed a classiﬁcation of the
ifferent types of PRP, according to the platelet count, the acti-
ator used, and the presence of white blood cells. This system
as  called PAW (Platelets, Activation and White Blood Cells).
he classiﬁcation, however, is complex and its practical sig-
iﬁcance has not been established yet.
In general, there are two basic types of platelet-rich plasma
ompounds: the platelet-rich plasma, obtained by double cen-
rifugation of blood together with an anticoagulant (citrate in
eneral); and platelet rich in growth factors (PRGF) obtained
hrough a single centrifugation, also with an anticoagulant
gent. However, there is no standardization for its obtainment,
nd each study has its own method.
linical  applications  of  platelet-rich  plasma
RP has been utilized in various clinical situations in order
o regenerate tissues. It is currently used in the treatment
f soft tissue lesions, such as repair of chronic ulcers,15
endinopathies and fasciitis.16 Its use in dental procedures,
uch as periodontal regeneration in dental implants,17 bone
egeneration in grafts18 and fractures, is also noteworthy.19
The action of the PRP began to be studied in osteoarthritis
n order to increase the anabolic activity of chondrocytes. The
latelet-rich plasma is capable of inducing proliferation of
20esenchymal cells, as demonstrated in vitro by Huang et al.
nd Kilian et al.21 PRP can regulate the action of metallopro-
einases and activate mechanisms of matrix regenerators
uch as the synthesis of collagen and proteoglycans.22ber of studies.
Nakagawa et al.23 demonstrated the in vitro efﬁcacy of PRP
stimulating chondrocyte proliferation and synthesis of colla-
gen. Mishra et al.24 showed that the platelet-rich plasma can
lead to proliferation of ﬁbroblasts in vitro, as well as stimulate
the expression of genes responsible for the chondrogenic and
osteogenic differentiation.
PRP  controlled  trials  versus  hyaluronic  acid  or  placebo
Sánchez et al.25 in 2012, in a double-blind, randomized trial,
compared the PRP and hyaluronic acid in 176 patients with
knee OA. The scores used for the analysis were WOMAC (West-
ern Ontario McMasters Universities Osteoarthritis Index) and
Lequesne. Treatment with PRP reduced by 50% the WOMAC
index (primary outcome) and showed a trend of improvement
in secondary outcomes, however with no statistical signif-
icance. The limitations mentioned by the author were no
comparison between the level of physical activity before and
after treatment, the short follow-up, the lack of a placebo
group and the exclusion of cases considered to be severe on
radiographic examination.
Vaquerizo et al.26 published in 2013 a study with similar
design to the study by Sanchez, where 96 patients were eval-
uated for 48 weeks. The PRP showed better responses in all
parameters analyzed, both in 24 and in 48 weeks, including
the percentage of responders of OMERACT-OARSI (Outcome
Measures for Rheumatology Committee and Osteoarthritis
Research Society International Standing Committee for Clini-
cal Trials Response Criteria Initiative).
Another study published in 2013 conducted by Say et al.,27compared a single PRP injection with three hyaluronic acid
(HA) injections in individuals with knee osteoarthritis. Clinical
evaluation was made by KOOS (Knee injury and Osteoarthri-
tis Outcome Score) and VAS (Visual Analog Scale) scores.
 o l . 2160  r e v b r a s r e u m a t
The study showed clinical improvement with both treatments
after three and six months of the procedures, however, with
a better response in patients treated with PRP. Furthermore,
the cost of treatment was lower in the group treated with PRP.
The limitations mentioned by the author were no patients ran-
domization and the exclusive use of clinical parameters in the
results analysis.
Li et al.28 in 2011, conducted a randomized study com-
paring the use of PRP and HA in 30 patients with knee
osteoarthritis. Both groups showed improvement in WOMAC
and IKDC indicators (International Knee Documentation Com-
mittee), maintaining similar efﬁcacy up to the fourth month of
follow-up and superiority of PRP in the sixth month. The short
follow-up period does not allow the evaluation of the duration
of the response, but points to the trend of a more  sustained
response of platelet-rich plasma.
Spaková et al.29 in 2012, in a randomized study, fol-
lowed 120 patients for six months with knee osteoarthritis:
60 received PRP and 60 HA. The group receiving PRP pre-
sented better improvement compared to HA when assessed
by WOMAC and the NRS (Numerical Rating Scale).
Cerza et al.30 compared PRP and HA in 120 patients with
knee osteoarthritis followed for 24 weeks. The assessment by
the WOMAC showed better responses with PRP, regardless of
the degree of joint damage (assessed by the Kellgren-Lawrence
classiﬁcation), contrasting with HA which was ineffective in
treating osteoarthritis grade III.
In 2012, Filardo et al.31 also compared PRP with HA in
109 patients with osteoarthritis of the knee through a ran-
domized double-blind study. The patients were evaluated by
IKDC, EQ-VAS (visual analog scale EuroQol), Tegner and KOOS
scores over a period of 12 months. Both groups showed clin-
ical improvement, with no difference between them. When
comparing the groups regarding the degree of osteoarthritis
in the scale of Kellgren-Lawrence, only a trend toward better
response from PRP in milder degree (degrees ≤ II) was found.
Kon et al.32 in 2011 treated three groups of 50 patients with
knee osteoarthritis who  received PRP, high and low molecular
weight HA respectively. A random distribution of patients was
not carried out among the three groups, since the treatment
performed was dependent on the center where the injections
were performed, with each institution being responsible for
the application of a single substance. Clinical response mea-
sured by the IKDC and EQ-VAS scores was higher in patients
that received PRP injections compared to HA. The low molec-
ular weight HA performed better than the high molecular
weight; however, still lower than the response obtained by
PRP.
Patel et al.33 in 2013 selected 74 patients with knee
osteoarthritis and divided them randomly into three groups:
those that received a single PRP injection (n = 26); those who
received two PRP injections 3-weeks apart (n = 25) and the
third group (n = 23) who  received a single placebo injection of
normal saline. The groups were assessed by WOMAC score by
an observer blinded to treatment status for 24 weeks. There
was a signiﬁcant improvement in both groups receiving inter-
vention, with a tendency to decrease in the last assessment
at six months. Regarding the number of injections, there
was no increase in response to treatment with an additional
application. 0 1 6;5 6(2):152–164
Non-controlled  studies  and  retrospective  cohort
In a retrospective cohort study, Sánchez et al.34 evaluated two
groups of 30 patients with knee OA who were treated with
PRP and HA inﬁltrations, respectively. Patients were evaluated
by WOMAC (pain domain as the primary outcome), compar-
ing baseline data with those obtained after ﬁve weeks of
injections. There was a better response of patients treated
with PRP compared to HA. As this was a retrospective study
and based on data reviewed in the medical records, the lack
of some information, such as mean disease duration and
use of analgesics, may have jeopardized the analysis of the
data.
Kon et al.35 conducted a prospective study in 2010 in
which 100 patients with knee osteoarthritis were treated with
PRP and evaluated at six and twelve months through IKDC
and EQ-VAS scales. There was a favorable response in the
ﬁrst six months, not sustained after twelve months, despite
remaining signiﬁcantly above the initial scores. Another study
by the same group, with similar methods, published in 2010
by Filardo et al.36 demonstrated a positive response in the ﬁrst
twelve months, which was not sustained until the end of the
second year of follow-up.
Sampson et al.37 in 2010 evaluated the use of PRP in knee
OA in 14 patients using the KOOS and Brittberg-Peterson VAS
scores, and followed them for 52 weeks. There was a signiﬁ-
cant clinical improvement in patients treated with PRP.
Ana Wang-Saegusa et al.38 conducted a study with 216
patients with knee OA that received PRP injection, assessed by
VAS scores, SF-36 (Short Form 36 Health Survey), WOMAC and
Lequesne for six months. All indexes showed improvement in
clinical parameters evaluated.
Napolitano et al.39 injected PRP in 27 patients with degen-
erative diseases of the knee, divided into two groups: those
with osteoarthritis and those with cartilage diseases (not spec-
iﬁed). Using the WOMAC and NRS questionnaires, there was
an early and sustained response for six months follow up
in both groups. As limitations, the author does not specify
the selection criteria and the study lacks statistical analysis,
which prevents the interpretation of results.
Sanchez et al.40 studied the effect of PRP injection in 40
patients with unilateral hip OA. The indices used for evalu-
ation were WOMAC, VAS and HHS (Harris Hip Score). There
was a positive response to PRP and the patients who  did not
respond had more  severe osteoarthritis on radiographic exam-
ination.
In 2012, Jang et al.41 studied the effect of a single application
of PRP in 65 patients with knee osteoarthritis. The patients
showed a favorable response in the VAS for pain, and IKDC up
to six months after treatment, which was not sustained after
one year of the injection.
In a pilot study, Battaglia et al.42 checked the effect of PRP
in 20 patients with hip OA, assessed by HHS and WOMAC
for 12 months. There was a signiﬁcant improvement between
the ﬁrst and third months, with a progressive decrease in
the response thereafter. After one year, the indices remained
above baseline.
In another pilot study conducted by Halpern et al.,43 the
responses to a single PRP injection in 17 patients with knee
osteoarthritis were assessed by VAS and WOMAC. Both pain
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nd functional indices were signiﬁcantly reduced at six and
welve months compared to baseline.
se  of  PRP  in  previous  surgical  interventions
obbi et al.44 in 2012 studied the PRP application on the
nee of 50 individuals, subdividing them also in patients who
ad undergone surgery in this joint and others with no prior
pproaches. Surgical procedures considered in this study were
he arthroscopic debridement and microfractures. The instru-
ents used were KOOS, VAS, Tegner, IKDC and Marx. A clinical
mprovement was observed in the patients after injection of
RP regarding pain, function and return to usual activities,
egardless of surgery performed.
In 2013, Hart et al.45 performed a sequence of nine PRP
pplications after undergoing arthroscopy in 50 patients with
nee OA. The assessment tools were Lyshcolm, Tegner, IKDC
nd Cincinnati scores. There was an improvement of the
ndices after six months of treatment, which was not main-
ained after 12 months.
RP  obtained  from  single  versus  double  centrifugation
egarding the technique for obtaining platelet-rich plasma,
ilardo et al.46 in 2011 conducted a study with 144 patients
ith knee osteoarthritis, comparing the acquisition of
latelets concentrate by single (plasma rich in growth fac-
ors – PRGF) or double centrifugation (PRP). It was found that
he beneﬁt was similar in both groups using the IKDC, EQ
AS and Tegner scores. However, adverse events (especially
ocal arthritis) occurred more  often in the PRP obtained by
ouble centrifugation, due to higher leukocyte concentration
roduced by this method.
RP  efﬁcacy  evaluation  through  imaging  methods
here is no consistent evidence regarding the effectiveness
f PRP measured by imaging methods. Some non-controlled
eries point to a possible stabilization of cartilage loss.
Sampson et al.37 in 2010, in addition to clinical response
ssessment previously described, performed a joint ultra-
ound to measure the articular cartilage thickness one
ear after PRP injection in 14 patients studied. The results
howed no beneﬁt in increasing the thickness of the artic-
lar cartilage, which does not mean a negative result, since
he method sensitivity is low for the detection of small
hanges.
Dhollander et al.47 in 2011 treated ﬁve patients with
hondral lesions of the patella with cartilage debridement,
ollowed by placement of a collagen membrane and PRP. The
atients were evaluated by magnetic resonance imaging (MRI)
efore the procedure and after 12 and 24 months. Bene-
ts were observed in clinical scores (VAS, KOOS subscale),
xcept for the Tegner score. However, there was no differ-
nce in MOCART score (Magnetic Resonance Observation of
artilage Tissue Repair), and only stability of the lesions took
lace.
Hart et al.45 in 2013 evaluated PRP response in 50 patients
ith knee OA by MRI  before and one year after the injection.
he degree of cartilage damage was measured by modiﬁed 6;5 6(2):152–164 161
Outerbridge Grading Scale. Cartilage thickness remained
unchanged in 94% of cases and a slight increase (less than
1 mm)  was recorded in three cases (6%). There was no control
group.
In a pilot study, Halpern et al.43 also evaluated, in a
non-controlled manner, the articular cartilage of 17 patients
undergoing PRP injection, using knee MRI. There was no
reduction in cartilage thickness during the year analyzed.
Considering that there is an annual fall of 4% to 6% in the
volume of articular cartilage in osteoarthritis,47 the authors
conclude that PRP can have a chondroprotective action.
Side  effects
Side effects related to injection of platelet-rich plasma are con-
sidered uncommon and, when present, usually manifest in a
mild and self-limited form.
Local symptoms are the most common adverse events,
ranging from pain at the injection site to signs of arthritis.
Filardo et al.46 in 2011 showed that the way of obtainment
of PRP inﬂuences the degree of intra-articular inﬂammatory
response, with this effect being attributed to the number of
leukocytes present in the inﬁltrate. Allergic reactions are pos-
sible but rare effects since it is an autologous product. The
most feared complication is the intra-articular infection that
can be prevented by performing the aseptic procedure.
In the studies selected from this review, the most fre-
quently reported adverse events were arthralgia in the
injected joint, whose intensity varied from mild to moder-
ate, and its resolution occurred in days, extending to weeks
in the most severe cases. Dhollander et al.47 reported a case
of hypertrophy of the regenerated cartilage tissue diagnosed
by an arthroscopy performed because of the patient’s symp-
toms, and was resolved by local debridement. Sánchez et al.40
reported a case of rash after the injection, the resolution of
which was spontaneous, with no need for speciﬁc treatment.
Filardo et al.31 demonstrated that higher post-injection pain
was noted in those patients injected with PRP compared to
HA. Systemic symptoms and infections were not reported in
the analyzed studies.
Final  considerations
In this review seven randomized controlled trials were found,
which showed a great methodological diversity, both in design
and in procedure for obtainment and injection of PRP. Of
these, only one33 used the placebo comparison. The other con-
trol groups received intra-articular hyaluronic acid, although
there is no consensus in the literature about its effective-
ness in the treatment of osteoarthritis.48 Only one of the
controlled studies25 deﬁned the degree of pain in the sample
selection, which is a signiﬁcant methodology gap, considering
the frequent clinical-imaging dissociation in osteoarthritis.
In addition, some studies included patients with minimal
and maximal radiographic grade (grades 1 and 4 Kellgren-
Lawrence respectively). However, level 1 is not completely
speciﬁc to osteoarthritis, and grade 4 corresponds to the ter-
minal illness. In 3 studies there was no concern with the
correct blinding mode, which would only be possible with the
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adoption of an appropriate SHAM procedure. There were dif-
ferences or lack of data in the range and number of injections,
administered volume and platelet concentration. The assess-
ment tools also varied, and only one study26 used OMERACT.
There are numerous other differences among the studies,
as shown in Table 1. This large variability was also recently
appointed in an interesting review,3 with the conclusion that
more controlled studies about the subject are necessary.
Despite the methodological heterogeneity and gaps in the
designs, Chang et al.,49 in 2013, published a meta-analysis on
the use of PRP in patients with knee osteoarthritis. The quality
of the work was measured by Jadad score, with the selection
of 16 papers. The analysis was based on the choice of only
one of the scores used in each article, establishing the fol-
lowing priority: IKDC, KOOS and WOMAC. The results showed
higher efﬁcacy and durability of treatment with PRP compari-
son with the control group. The author exposes the limitations
of the meta-analysis, highlighting the lack of standardization
in methods for PRP obtainment, the different scores used in
the work, resulting in a heterogeneous data analysis; and the
inclusion of patients with Kellgren-Lawrence scale of zero in
some studies.
In the same year a systematic review by Khoshbin et al.
was published.50 Their assessment was based in scales that
consider randomization, blinding, results, measurements,
inclusion and exclusion criteria, description of treatment and
statistical analysis. In the end, six studies were selected.
A beneﬁt of PRP was observed compared to control groups
(hyaluronic acid and saline) in WOMAC score in four studies
and IKDC in three studies, but no beneﬁts in other criteria such
as visual scale of pain and patient satisfaction scores. Adverse
events were more  frequent in the group receiving PRP.
We conclude that, based on randomized controlled stud-
ies, PRP seems to produce improvement in pain and joint
function in knee osteoarthritis, both compared to placebo and
hyaluronic acid. The response can be sustained for a period of
up to two years, and seems to be more  evident in milder cases
of OA. There is no consistent evidence of the action of PRP on
the cartilage measured by imaging.
Although PRP seems to be an effective option, caution is
required in interpreting the results. In most studies the sample
is small, the period of observation short and OA characteristics
have not been fully described. The comparison of the results
is complicated by the lack of standardization in the collection
and application of PRP regimen.
Thus, more  randomized, prospective studies with appro-
priate design are needed to conﬁrm the actual PRP role in
osteoarthritis.
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